Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study.

被引：0
|
作者：
Hompland, Ivar
Boye, Kjetil
Papakonstantinou, Andri
Rosok, Bard
Joensuu, Heikki
Bruland, Oyvind
机构：
[1] Oslo Univ Hosp, Oslo, Norway
[2] Karolinska Univ Hosp, Stockholm, Sweden
[3] Univ Helsinki, Cent Hosp, Helsinki, Finland
[4] Oncoinvent AS, Oslo, Norway
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study
    Hompland, Ivar
    Boye, Kjetil
    Wiedswang, Anne Marit
    Papakonstantinou, Andri
    Rosok, Bard
    Joensuu, Heikki
    Bruland, Oyvind
    ACTA ONCOLOGICA, 2024, 63 : 288 - 293
  • [2] A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor
    Ryu, Min-Hee
    Kang, Won Ki
    Bang, Yung-Jue
    Lee, Kyung Hee
    Shin, Dong Bok
    Ryoo, Baek-Yeol
    Roh, Jae Kyung
    Kang, Jin-Hyoung
    Lee, Hyoungnam
    Kim, Tae Won
    Chang, Heung Moon
    Park, Joon Oh
    Park, Young Suk
    Kim, Tae-You
    Kim, Min Kyoung
    Lee, Woon Kee
    Kang, Hye Jin
    Kang, Yoon-Koo
    ONCOLOGY, 2009, 76 (05) : 326 - 332
  • [3] A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.
    Ryu, M.
    Park, S. H.
    Ryoo, B.
    Im, S.
    Kwon, H.
    Lee, S. S.
    Park, S. R.
    Kang, B. W.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Case 3.: Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate
    Chacón, M
    Roca, E
    Huertas, E
    Loria, FS
    Domenechini, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) : 1580 - 1582
  • [5] Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study
    Yang, Dong
    Hu, Xueying
    Ruan, Lin
    Yang, Zhendong
    Zhang, Tingting
    Qin, Yutao
    Liu, Kang
    Liang, Fangfang
    Qin, Yating
    Huang, Heqing
    Li, Pian
    Du, Guobo
    Lu, Ying
    Han, Yaqian
    Wang, Rensheng
    Kang, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
    Trent, J. C.
    Wathen, K.
    von Mehren, M.
    Samuels, B. L.
    Staddon, A. P.
    Choy, E.
    Butrynski, J. E.
    Chugh, R.
    Chow, W. A.
    Rushing, D. A.
    Forscher, C. A.
    Baker, L. H.
    Schuetze, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Y-K Kang
    C Yoo
    B-Y Ryoo
    J J Lee
    E Tan
    I Park
    J H Park
    Y J Choi
    J Jo
    J-S Ryu
    M-H Ryu
    British Journal of Cancer, 2013, 109 : 2309 - 2315
  • [8] Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Kang, Y-K
    Yoo, C.
    Ryoo, B-Y
    Lee, J. J.
    Tan, E.
    Park, I.
    Park, J. H.
    Choi, Y. J.
    Jo, J.
    Ryu, J-S
    Ryu, M-H
    BRITISH JOURNAL OF CANCER, 2013, 109 (09) : 2309 - 2315
  • [9] A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood
    Zhou, Ye
    Zhang, Xinhua
    Wu, Xiaojun
    Zhou, Yongjian
    Zhang, Bo
    Liu, Xiufeng
    Wu, Xin
    Li, Yan
    Shen, Lin
    Li, Jian
    CANCER MEDICINE, 2020, 9 (17): : 6225 - 6233
  • [10] A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
    George, S.
    von Mehren, M.
    Heinrich, M. C.
    Wang, Q.
    Corless, C. L.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    Choy, E.
    Tap, W. D.
    Manola, J.
    Yap, J. T.
    Van den Abbeele, A. D.
    Solomon, S.
    Fletcher, J. A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345